Literature DB >> 19401364

Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.

Mario Durán-Prado1, Manuel D Gahete, Antonio J Martínez-Fuentes, Raúl M Luque, Ana Quintero, Susan M Webb, Pedro Benito-López, Alfonso Leal, Stefan Schulz, F Gracia-Navarro, María M Malagón, Justo P Castaño.   

Abstract

CONTEXT: Somatostatin and its related peptide cortistatin exert multiple actions on normal and tumoral tissue targets through a family of receptors termed somatostatin receptor (sst)1-5. Despite the considerable advances in the knowledge on these receptors and their (patho)physiological roles, there is still evidence that additional receptors for these peptides should exist to fully explain their actions.
OBJECTIVE: The growing number of spliced variants found in similar receptor families, often present in tumors, and results from our group obtained on sst5 from other species (pig) led us to explore the existence of new human sst5 isoforms. DESIGN AND
RESULTS: A rapid amplification of cDNA ends PCR approach on samples from a human pituitary tumor and a cell line enabled identification of two novel alternatively spliced sst5 receptor variants. The sequences obtained encode putative proteins that correspond to truncated isoforms of five and four transmembrane domains (TMDs), accordingly named sst5TMD5 and sst5TMD4, respectively. Both novel receptors show a differential expression pattern in normal tissues and are also present in pituitary tumors of diverse etiology including nonfunctioning adenomas, corticotropinomas, somatotropinomas, and a prolactinoma. In contrast to the predominant plasma membrane localization of full-length sst5, both sst5TMD5 and sst5TMD4 show a preferentially intracellular localization. Despite their truncated nature, both receptors are functional, as shown by their ability to mediate selective, ligand-induced rises in free cytosolic calcium concentration. Specifically, whereas sst5TMD5 is selectivity activated by somatostatin compared with cortistatin, cells transfected with sst5TMD4 almost exclusively respond to cortistatin and not to somatostatin.
CONCLUSIONS: Our results demonstrate the existence of two previously unidentified sst5 spliced variants with distinct distribution in normal tissues and pituitary tumors, unique ligand-selective signaling properties, and subcellular distribution, which could contribute to somatostatin and cortistatin signaling in normal and tumoral cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401364     DOI: 10.1210/jc.2008-2564

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  41 in total

1.  Discrimination between alternate membrane protein topologies in living cells using GFP/YFP tagging and pH exchange.

Authors:  Beatriz Domingo; María Gasset; Mario Durán-Prado; Justo P Castaño; Antonio Serrano; Thierry Fischer; Juan Llopis
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

Review 2.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  Somatostatin receptor ligands in the treatment of acromegaly.

Authors:  Monica R Gadelha; Luiz Eduardo Wildemberg; Marcello D Bronstein; Federico Gatto; Diego Ferone
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

5.  Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.

Authors:  Raúl M Luque; Alejandro Ibáñez-Costa; Leonardo Vieira Neto; Giselle F Taboada; Daniel Hormaechea-Agulla; Leandro Kasuki; Eva Venegas-Moreno; Alberto Moreno-Carazo; María Ángeles Gálvez; Alfonso Soto-Moreno; Rhonda D Kineman; Michael D Culler; Manuel D Gahete; Mônica R Gadelha; Justo P Castaño
Journal:  Cancer Lett       Date:  2015-01-28       Impact factor: 8.679

6.  The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells.

Authors:  Daniela Molè; Erica Gentilin; Alejandro Ibañez-Costa; Teresa Gagliano; Manuel D Gahete; Federico Tagliati; Roberta Rossi; Maria Rosa Pelizzo; Giancarlo Pansini; Raúl M Luque; Justo P Castaño; Ettore degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2015-04-09       Impact factor: 3.633

Review 7.  Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Ning-Ai Liu; Shlomo Melmed
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 8.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

Review 9.  Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.

Authors:  Andreas Stengel; Jean Rivier; Yvette Taché
Journal:  Peptides       Date:  2012-12-31       Impact factor: 3.750

Review 10.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.